Targeted radiation zaps advanced prostate cancer in new trial
Disease control
Recruiting now
This study is testing a new radioactive drug called lutetium (177Lu) rhPSMA-10.1 for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapies. The goal is to find a safe and effective dose that can shrink tumors by delivering rad…
Phase: PHASE1, PHASE2 • Sponsor: Blue Earth Therapeutics Ltd • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC